Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults

BACKGROUND: Shigellosis accounts for substantial morbidity and mortality worldwide and is the second most common cause of moderate and severe diarrhoea in children. METHODS: This phase 2b study (NCT03527173), conducted between August 2018 and November 2019, evaluated vaccine efficacy (VE), safety, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Frenck, Robert W., Conti, Valentino, Ferruzzi, Pietro, Ndiaye, Augustin G.W., Parker, Susan, McNeal, Monica Malone, Dickey, Michelle, Granada, Juan Paolo, Cilio, Giulia Luna, De Ryck, Iris, Necchi, Francesca, Suvarnapunya, Akamol E., Rossi, Omar, Acquaviva, Alessandra, Chandrasekaran, Lakshmi, Clarkson, Kristen A., Auerbach, Joachim, Marchetti, Elisa, Kaminski, Robert W., Micoli, Francesca, Rappuoli, Rino, Saul, Allan, Martin, Laura B., Podda, Audino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367798/
https://www.ncbi.nlm.nih.gov/pubmed/34430837
http://dx.doi.org/10.1016/j.eclinm.2021.101076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367798/
https://www.ncbi.nlm.nih.gov/pubmed/34430837
http://dx.doi.org/10.1016/j.eclinm.2021.101076

Ejemplares similares